These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 30837904)

  • 21. The endocannabinoid system as a target for addiction treatment: Trials and tribulations.
    Sloan ME; Gowin JL; Ramchandani VA; Hurd YL; Le Foll B
    Neuropharmacology; 2017 Sep; 124():73-83. PubMed ID: 28564576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Research Domain Criteria Approach to Gambling Disorder and Behavioral Addictions: Decision-Making, Response Inhibition, and the Role of Cannabidiol.
    Pallanti S; Marras A; Makris N
    Front Psychiatry; 2021; 12():634418. PubMed ID: 34603091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials.
    Bitencourt RM; Takahashi RN
    Front Neurosci; 2018; 12():502. PubMed ID: 30087591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Pro-neurogenic Effects of Cannabidiol and Its Potential Therapeutic Implications in Psychiatric Disorders.
    Luján MÁ; Valverde O
    Front Behav Neurosci; 2020; 14():109. PubMed ID: 32676014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review.
    Batalla A; Janssen H; Gangadin SS; Bossong MG
    J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31330972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.
    White CM
    J Clin Pharmacol; 2019 Jul; 59(7):923-934. PubMed ID: 30730563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle.
    Gonzalez-Cuevas G; Martin-Fardon R; Kerr TM; Stouffer DG; Parsons LH; Hammell DC; Banks SL; Stinchcomb AL; Weiss F
    Neuropsychopharmacology; 2018 Sep; 43(10):2036-2045. PubMed ID: 29686308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives.
    Scherma M; Muntoni AL; Melis M; Fattore L; Fadda P; Fratta W; Pistis M
    Psychopharmacology (Berl); 2016 May; 233(10):1765-77. PubMed ID: 26728894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer's Disease.
    Hickey JP; Collins AE; Nelson ML; Chen H; Kalisch BE
    Curr Issues Mol Biol; 2024 May; 46(5):4379-4402. PubMed ID: 38785534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabidiol Inhibits Endocannabinoid Signaling in Autaptic Hippocampal Neurons.
    Straiker A; Dvorakova M; Zimmowitch A; Mackie K
    Mol Pharmacol; 2018 Jul; 94(1):743-748. PubMed ID: 29669714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory Status of Cannabidiol in the United States: A Perspective.
    Corroon J; Kight R
    Cannabis Cannabinoid Res; 2018; 3(1):190-194. PubMed ID: 30283822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of the endogenous cannabinoid system in drug addiction.
    Parolaro D; Rubino T
    Drug News Perspect; 2008 Apr; 21(3):149-57. PubMed ID: 18560613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction.
    Olière S; Joliette-Riopel A; Potvin S; Jutras-Aswad D
    Front Psychiatry; 2013 Sep; 4():109. PubMed ID: 24069004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of cannabidiol's inhibitory effect on alpha-glucosidase and its stability in simulated gastric and intestinal fluids.
    Ma H; Li H; Liu C; Seeram NP
    J Cannabis Res; 2021 Jun; 3(1):20. PubMed ID: 34162444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cannabinoid interactions with ion channels and receptors.
    Watkins AR
    Channels (Austin); 2019 Dec; 13(1):162-167. PubMed ID: 31088312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabidiol and the Remainder of the Plant Extract Modulate the Effects of Δ9-Tetrahydrocannabinol on Fear Memory Reconsolidation.
    Murkar A; Kent P; Cayer C; James J; Durst T; Merali Z
    Front Behav Neurosci; 2019; 13():174. PubMed ID: 31417379
    [No Abstract]   [Full Text] [Related]  

  • 37. New perspectives in the studies on endocannabinoid and cannabis: a role for the endocannabinoid-arachidonic acid pathway in drug reward and long-lasting relapse to drug taking.
    Yamamoto T; Anggadiredja K; Hiranita T
    J Pharmacol Sci; 2004 Dec; 96(4):382-8. PubMed ID: 15599102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders.
    Baswan SM; Klosner AE; Glynn K; Rajgopal A; Malik K; Yim S; Stern N
    Clin Cosmet Investig Dermatol; 2020; 13():927-942. PubMed ID: 33335413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence.
    Rohleder C; Müller JK; Lange B; Leweke FM
    Front Pharmacol; 2016; 7():422. PubMed ID: 27877130
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.